Format

Send to

Choose Destination
See comment in PubMed Commons below
Leuk Lymphoma. 2011 Jun;52(6):1085-97. doi: 10.3109/10428194.2011.555891. Epub 2011 Mar 21.

The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma.

Author information

  • 1Department of Biological Sciences, Purdue University, West Lafayette, IN 47907, USA.

Abstract

Multiple myeloma (MM) is an incurable plasma cell malignancy where nearly all patients succumb to a relapse. The current preclinical models of MM target the plasma cells, constituting the bulk of the tumor, leaving the cancer stem cells to trigger a relapse. Utilizing a three-dimensional tissue culture system where cells were grown in extracellular matrix designed to reconstruct human bone marrow, we tested the anti-multiple myeloma cancer stem cell (MM-CSC) potential of two natural product inhibitors of nuclear factor κB (NFκB). Here we show that parthenolide and andrographolide are potent anti-MM-CSC agents. Both natural products demonstrated preferential toxicity toward MM-CSCs over non-tumorigenic MM cells. Addition of the bone marrow stromal compartment abrogated andrographolide activity while having no effect on parthenolide cytoxicity. This is the first report of a natural product with anti-CSC activity in myeloma, suggesting that it has the potential to improve the survival of patients with MM by eliminating the relapse-causing MM-CSCs.

PMID:
21417826
DOI:
10.3109/10428194.2011.555891
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center